Browsing Tag
International Congress of Parkinson’s Disease and Movement Disorders
1 post
Arvinas reports robust phase 1 signals for ARV-102 LRRK2 degrader at MDS 2025, pointing to meaningful target knockdown and brain penetration
Find out how Arvinas’ ARV-102 delivered strong Phase 1 LRRK2 knockdown and brain exposure at MDS 2025—and what it could mean for Parkinson’s trials next.